To evaluate the degradation efficiency of FolTAC v0.2 on single targets in cancers and immune-oncology, we engineered various FolTACs to target and degrade TfR1, EGFR, HER2, PD-L1, and VISTA (Fig. 1g and Supplementary Fig. 2d, e). This evidence concerns the gene CD274 and cancer.